Cost effectiveness, quality-adjusted life-years and supportive care: Recombinant human erythropoietin as a treatment of cancer-associated anaemia

PharmacoEconomics

Volumn 16, Issue 5, 1999, Pages 459-472

  Cremieux, Pierre Yves ^a,b   Finkelstein, Stan N ^c   Berndt, Ernst R ^c   Crawford, Jeffrey ^d   Slavin, Mitchell B ^e  

^a Analysis Group/Economics   (United States)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0032733968     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916050-00004     Document Type: Article

References (22)

1. Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 1993; 29A: S2-8
2. Case D, Bukowski R, Carey R, et al. Recombinant-human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85 (10): 801-6
3. Glaspy J, Bukowski R, Steinberg D, et al. The impact of therapy with epoetin alfa on clinical outcomes during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218-34
4. Demetri G, Kris M, Wade J, et al. Quality-of-lite benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16 (10): 3412-25
5. Sheffield R, Sullivan S, Saltiel B, et al. Cost comparison of recombinant human crythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31: 15-22
6. Finkelstein S, Huber S, Greenberg P, Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31: 1094
7. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78 (6): 781-7
8. Ortega A, Dranitsaris G, Puodziunas ALV. What are cancer patients willing to pay for prophylactic epoetin alfa. Cancer 1998; 83 (12): 2588-96
9. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
10. Padilla GV, Grant MM, Ferrell, et al. QL and cancer. In: Spilker B, editor. Quality-of-life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 301-8
11. McCormack H, Home D, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988; 18: 1007-19
12. Shulman K, Linas B. Pharmacoeconomics: state of the art in 1997. Annu Rev Public Health 1997; 18: 529-48
13. Yellen S, Cella D, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74
14. Cantor S, Hudson D, Lichtiger B, et al. The costs of blood transfusion: a process flow analysis. J Clin Oncol 1998; 16: 2364-70
15. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995; 35: 427-30
16. Health Care Financing Administration (HCFA). Part B extract summary system. Baltimore (MD): HCFA, 1997
17. American Cancer Society. Estimated new cancer cases [on line]. Available from: URL: http://www.cancer.org/statistics/cff98-/graphicaldata.html. [accessed 1999 Aug II]
18. Mehrez A, Gafni A. Healthy-year equivalent versus quality-adjusted life years: in pursuit of progress. Med Decis Making 1993; 13 (4): 287-92
19. Nord E. The validity of a visual analogue scale in determining social utility weights lor health states. Int J Health Plann Manage 1991; 6: 234-42
20. Leplège A, Hunt S. The problem of QL in medicine. JAMA 1997; 278: 47-50
21. Crown WH, Obenchain RL, Englehart L, et al. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med 1998; 17: 1943-58
22. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33-64